National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002
National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002
复制标题
DOI：
10.1128/aac.48.12.4606-4610.2004
复制
发表时间：
2004-12-01
影响因子：
4.9
通讯作者：
Jung, R
中科院分区：
文献类型：
--
作者：
Obritsch, MD;Fish, DN;Jung, R
由铜绿假单胞菌引起的医院感染在危重患者中往往难以治疗，因为对多种抗菌素具有耐药性。本研究的目的是利用重症监护病房监测研究数据库，评估1993年至2002年美国重症监护病房患者中铜绿假单胞菌分离株的抗菌素耐药性。对13999株铜绿假单胞菌进行了10年的药敏分析。从1993年到2002年，全国范围内抗菌素耐药性增加最多的是环丙沙星、亚胺培南、妥布霉素和阿唑南。多药耐药率（对下列药物：头孢他啶、环丙沙星、妥布霉素和亚胺培南2:3的耐药率）从1993年的4%上升到2002年的14%。氨基糖苷类或氟喹诺酮类药物与哌拉西林-他唑巴坦的双重耐药率最低，而与内酰胺类药物和环丙沙星的双重耐药率最高。正在进行的监测研究对于监测抗菌素敏感性模式和选择经验性治疗方案至关重要。
Nosocomial infections caused by Pseudomonas aeruginosa in critically ill patients are often difficult to treat due to resistance to multiple antimicrobials. The purpose of this study was to evaluate antimicrobial resistance among P. aeruginosa isolates from intensive care unit patients in the United States from 1993 to 2002 by using the Intensive Care Unit Surveillance Study database. Over the 10-year period, susceptibility of 13,999 nonduplicate isolates of P. aeruginosa was analyzed. From 1993 to 2002, nationwide increases in antimicrobial resistance were greatest for ciprofloxacin, imipenem, tobramycin, and aztreonam. Rates of multidrug resistance (resistance to 2:3 of the following drugs: ceftazidime, ciprofloxacin, tobramycin, and imipenem) increased from 4% in 1993 to 14% in 2002. The lowest dual resistance rates were observed between aminoglycosides or fluoroquinolones with piperacillin-tazobactam while the highest were for those that included beta-lactams and ciprofloxacin. Ongoing surveillance studies are crucial in monitoring antimicrobial susceptibility patterns and selecting empirical treatment regimens.